0.31
-28.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Avenue Therapeutics
From its filings with the US Securities and Exchange Commission
Avenue Therapeutics is based in Bay Harbor Islands, Florida and is incorporated in Delaware. Its shares trade on OTC under the ticker ATXI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.4m and a net loss of $2.9m. At that date it held total assets of $2.9m and shareholders' equity of $1.8m.
Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Our current product candidates are ATX-04, a selective β2-adrenergic agonist for Pompe disease, intravenous tramadol (“IV tramadol”), a schedule IV opioid for the treatment of post-operative acute pain and previously, through November 5, 2025, BAER-101 for the treatment of epilepsy and panic disorders.
In February 2026, we announced the entry into an exclusive license agreement with Duke University for patents and know-how relating to clenbuterol (referred to as ATX-04), a selective β2-adrenergic agonist, for the treatment of lysosomal storage diseases with a focus on Pompe disease.
In November 2022, we completed a Stock Contribution Agreement, dated May 11, 2022 (the “Contribution Agreement”) with Fortress Biotech, Inc (“Fortress”) to acquire the shares in Baergic Bio, Inc. (“Baergic”), which was developing BAER-101, a novel α2/3–subtype-selective gamma-aminobutyric acid ("GABA") A positive allosteric modulator (“PAM”). As a result, Baergic was a majority-controlled and owned subsidiary company of Avenue. On November 5, 2025, we announced we had entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (“Axsome”) including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM).
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jun 2017
- Employees
- 1
- Website
- avenuetx.com ↗
- Head office
- 1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL, 33154
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Jay KranzlerNon-Executive Chairman of the Board$174,530
- Dr. Alexandra MacleanChief Executive Officer, Director, since 2022$840,100
- Mr. David JinInterim Chief Financial Officer, Chief Operating Officer$155,350
- Dr. Lindsay RosenwaldDirector, since 2015$64,530
- Ms. Faith CharlesIndependent Director$114,530
- Mr. Neil HerskowitzIndependent Director$124,530
- Mr. Curtis OltmansIndependent Director$114,530
- Ms. Jaclyn JaffeInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 23
- Environment
- 24
- Social
- 25
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Avenue Therapeutics focuses on IV Tramadol for acute care hospital settings with 4 employees.
- The company leverages existing tramadol products like Ultram and Ultracet in the US market.
- Tramadol's dual-acting opioid properties offer a unique analgesic approach in post-operative pain management.
Weaknesses
- Avenue Therapeutics has only 4 full-time employees, limiting operational capacity.
- The company's sole focus on tramadol products creates dependency on a single drug.
- Limited commercialization experience with only one product candidate in development.
Opportunities
- Expanding IV Tramadol use in acute care hospital settings across the US market.
- Potential for new formulations of tramadol beyond current IV, IM, and SC options.
- Growing demand for post-operative pain management solutions in US hospitals.
Threats
- Competition from established pharmaceutical companies with broader product portfolios.
- Regulatory challenges in developing and commercializing new drug formulations.
- Market saturation with existing tramadol products like Ultram and Ultracet.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.